
# Drug Formulary Commission

**Bureau of Health Professions Licensure Department of Public Health**

**May 17, 2018**

**Slide 1**

**Presentation Agenda**

### Review of March 15th meeting

* Cost Impact Presentation
* Draft Formulary Regulations

*105 CMR 720: Drug Formulary Commission (FKA: List of Interchangeable Drug Products)*

#### Schedule

* + Guidance
* Remarks
* Next Steps

**Formulary Review and Evaluation**

Draft Amended Formulary

Component 3: “Cross Walk” – Chemically Equivalent Substitutions

Component 2: Interchangeable Abuse Deterrent Opioids

Component 1: Opioids with a Heightened Public Health Risk


# Drug Formulary Commission

**Cost Impact Presentation**

**Slide 4**

**Substitution Cost Algorithm**



**Chemically Equivalent Substitution Stratification Factors**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Element** | **Element Score** | **Factor Score** |
| **Substitution Factor***IAD-specific calculation* | IAD current market share |  |  |
| Length of approval |  |
| ADP efficacy |  |
| Routes of deterrence |  |
| Discounts available (Medicaid) |  |
| Generic available |  |
| HPHR of concern |  |
| ER or IR |  |
| **Public Health Factor***Potential costs/ savings/benefit Applied to all crosswalks* | Criminal Justice |  |  |
| Direct Healthcare (OUD treatment, OD/NFO response) |  |
| Ancillary Healthcare (first responders, NAS, disability) |  |
| Death |  |
| Prescribing/dispensing education |  |
|  |  |
|  |  |
| **Population Factor***Risk/value assessment**Applied to all crosswalks* | Medicaid/Medicare patient (2x scripts; 3-6x OUD) |  |  |
| First time script (36 months to OD/NFO) |  |
| Diversion (hospice/LTCF) |  |
| Co-morbid psych (opioid + benzo, etc.) |  |
|  |  |
|  |  |
|  |  |
| **TOTAL** |  |  | % |

**Promulgation of Regulation and Formulary**

History

* Proposed 105 CMR 720, *List of Interchangeable Drug Products,* including draft formulary, as redrafted, to the Public Health Council (PHC) (11/9/2016)
* Public hearing held on proposed changes to regulation (1/19/2017)
* DPH staff reviewed comments and further amended, including the addition of several new DFC approved IADs.
* Public hearing held on proposed changes to regulation (7/7/2017)
* PHC promulgated 105 CMR 720, *Drug Formulary Commission* (fka *List of Interchangeable Drug Products),* including draft formulary (8/9/2017)

Next Steps

* Issue guidance, including special substitution considerations, and the requirements and process of substitution.
* Review by Secretary of State Regulation becomes effective (TBD).
* Conduct prescriber education on abuse deterrent substitutes.

**Formulary Guidance Background**

#### This draft formulary is a tool for prescribers when continuing and initiating the treatment of pain.

* + Guidance will be issued approximately one month prior to the regulation, including the draft formulary, becoming effective.
	+ “No Substitution”
	+ The following items on a Schedule II prescription may not be changed by a pharmacist, pursuant to applicable DEA rules:
		- Name of Patient
		- Name of the Drug
		- Name of the Prescriber
		- Date of the Prescription

#### Prescriber unavailable

**Membership Terms**

|  |  |
| --- | --- |
| **Term Expires** | **Members** |
| June 10, 2018 | 4 |
| June 17, 2018 | 1 |
| June 23, 2018 | 1 |
| \*July 27, 2018 | 4 |
| August 6, 2018 | 1 |
| August 14, 2018 | 1 |
| August 17, 2018 | 1 |
| Ex Officio\* Next Meeting - July 19, 2018 | 3 |

**Meeting Schedule**

Tentative 3rd Thursday Schedule

~~• June 21, 2018~~

• July 19, 2018

• August 16, 2018 \*\*

\*\* Optional if *Non-opioid List update has not been completed. Update required by 8/30/18.*

**Meeting Summary**

* Meeting Recap
* Next Steps
* Next Meeting

### – July 19, 2018

#### – 9:00AM to 12:00PM

– @ 250 Washington Street (Boston, MA)